Pub Date : 2024-08-26DOI: 10.3390/pathophysiology31030032
Nana Fukushima, Yuki Miyamoto, Junji Yamauchi
Small GTP-binding proteins of the Rab family regulate intracellular vesicle trafficking across many aspects of the transport system. Among these, Rab9 is recognized for its role in controlling the transport system not only around the trans-Golgi network but also around the late endosome. However, the specific functions across different cell types and tissues remain unclear. Here, for the first time, we report that Rab9 negatively regulates morphological changes in the FBD-102b cell line, an oligodendroglial precursor cell line undergoing morphological differentiation. The knockdown of Rab9 led to an increase in cell shape alterations characterized by widespread membrane extensions. These changes were accompanied by increased expression levels of oligodendroglial cell differentiation and myelination marker proteins. Notably, the knockdown of Rab9 was capable of recovering defective cell morphological changes induced by tunicamycin, an inducer of endoplasmic reticulum (ER) stress, which is one of the major causes of oligodendroglial cell diseases such as Pelizaeus-Merzbacher disease (PMD, currently known as hypomyelinating leukodystrophy type 1 [HLD1]). In addition, Rab9 knockdown recovered levels of ER stress marker proteins and differentiation markers. Similar results were obtained in the cases of dithiothreitol (DTT), another chemical ER stress inducer, as well as HLD1-associated proteolipid protein 1 (PLP1) mutant protein. These results indicate a unique role for Rab9 in oligodendroglial cell morphological changes, suggesting its potential as a therapeutic target for mitigating diseases such as HLD1 at the molecular and cellular levels.
{"title":"Knockdown of Rab9 Recovers Defective Morphological Differentiation Induced by Chemical ER Stress Inducer or PMD-Associated PLP1 Mutant Protein in FBD-102b Cells.","authors":"Nana Fukushima, Yuki Miyamoto, Junji Yamauchi","doi":"10.3390/pathophysiology31030032","DOIUrl":"10.3390/pathophysiology31030032","url":null,"abstract":"<p><p>Small GTP-binding proteins of the Rab family regulate intracellular vesicle trafficking across many aspects of the transport system. Among these, Rab9 is recognized for its role in controlling the transport system not only around the trans-Golgi network but also around the late endosome. However, the specific functions across different cell types and tissues remain unclear. Here, for the first time, we report that Rab9 negatively regulates morphological changes in the FBD-102b cell line, an oligodendroglial precursor cell line undergoing morphological differentiation. The knockdown of Rab9 led to an increase in cell shape alterations characterized by widespread membrane extensions. These changes were accompanied by increased expression levels of oligodendroglial cell differentiation and myelination marker proteins. Notably, the knockdown of Rab9 was capable of recovering defective cell morphological changes induced by tunicamycin, an inducer of endoplasmic reticulum (ER) stress, which is one of the major causes of oligodendroglial cell diseases such as Pelizaeus-Merzbacher disease (PMD, currently known as hypomyelinating leukodystrophy type 1 [HLD1]). In addition, Rab9 knockdown recovered levels of ER stress marker proteins and differentiation markers. Similar results were obtained in the cases of dithiothreitol (DTT), another chemical ER stress inducer, as well as HLD1-associated proteolipid protein 1 (PLP1) mutant protein. These results indicate a unique role for Rab9 in oligodendroglial cell morphological changes, suggesting its potential as a therapeutic target for mitigating diseases such as HLD1 at the molecular and cellular levels.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"420-435"},"PeriodicalIF":2.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The present study aims to evaluate the effect of Sepia pharaonis ink on insulin resistance in PCOS-induced mice. Treatment with sepia ink in dehydroepiandrosterone (DHEA)-induced PCOS mice at various doses of 50 mg/kg, 100 mg/kg, and 200 mg/kg body weight mitigated the insulin resistance in the study groups with decreased concentration of testosterone and increased concentrations of estrogen and progesterone compared to the PCOS group tested by ELISA. The histopathological analysis and restoration of glucose analysis showed a significant reduction in treatment groups. Reduced expression of insulin resistance genes like androgen receptor (AR), insulin receptor substrate 1 (IRS-1), and insulin-like growth factor1 (IGF-1) by qRT-PCR indicate a positive impact of sepia ink in alleviating the symptoms associated with PCOS. Taken together, the results of this study indicate sepia ink as a promising therapeutic intervention and a possible drug target for insulin resistance in diabetes and gynecological disorders like PCOS.
{"title":"<i>Sepia pharaonis</i> Ink Mitigates Dehydroepiandrosterone-Induced Insulin Resistance in Mouse Model of Polycystic Ovarian Syndrome.","authors":"Prathyusha Yamarthi, Rama Satyasri Kotipalli, Samatasai Patnaik, Kv Veena, Muralidharan Kathirvel, Rajkumar Vutukuri, Manjula Bhanoori","doi":"10.3390/pathophysiology31030031","DOIUrl":"10.3390/pathophysiology31030031","url":null,"abstract":"<p><p>The present study aims to evaluate the effect of <i>Sepia pharaonis</i> ink on insulin resistance in PCOS-induced mice. Treatment with sepia ink in dehydroepiandrosterone (DHEA)-induced PCOS mice at various doses of 50 mg/kg, 100 mg/kg, and 200 mg/kg body weight mitigated the insulin resistance in the study groups with decreased concentration of testosterone and increased concentrations of estrogen and progesterone compared to the PCOS group tested by ELISA. The histopathological analysis and restoration of glucose analysis showed a significant reduction in treatment groups. Reduced expression of insulin resistance genes like androgen receptor (AR), insulin receptor substrate 1 (IRS-1), and insulin-like growth factor1 (IGF-1) by qRT-PCR indicate a positive impact of sepia ink in alleviating the symptoms associated with PCOS. Taken together, the results of this study indicate sepia ink as a promising therapeutic intervention and a possible drug target for insulin resistance in diabetes and gynecological disorders like PCOS.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"408-419"},"PeriodicalIF":2.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-12DOI: 10.3390/pathophysiology31030030
Kelli Morgan, James Morris, Qiang Cai, Phillip Kilgore, Urska Cvek, Marjan Trutschl, Katelynn T Lofton, Meher Sindhoora Mavuram, Prerana Ramesh, Nhi Dao, Ahmed Alhaque, Jonathan Steven Alexander
<p><p>Several studies have correlate improved patient outcomes with increased physician-patient contacts, particularly in chronic diseases. Extending this approach to inflammatory bowel disease (IBD) care presents a promising means of improving outcomes. At LSU Health Shreveport (LSUHS), a new approach called "STABILITY" (Symptomatic Review during Biologic Therapy) was implemented during infusion therapy visits for IBD patients. These brief 15 min physician-patient interviews aimed to discuss the patients' current IBD-related symptoms and evaluate the need for any changes in their treatment plan. Our goal was to remove a care gap and prevent intensifying symptoms created by missed appointments and loss of contact. To analyze the effectiveness of the STABILITY approach, a retrospective chart review was conducted on 111 IBD patients (18 with ulcerative colitis, 93 with Crohn's disease) seen at LSUHS between 2011 and 2022. Since March 2019, STABILITY has been mandatory for all infusion therapy visits. The data collected included patients' demographics, lab levels for biomarkers (fecal calprotectin, C-reactive protein, and erythrocyte sedimentation rates), hospitalizations, medication changes, and diagnosis dates before and after the implementation of STABILITY. Additionally, voluntary, anonymous infusion patient satisfaction surveys post-STABILITY were used to gather patient responses. In males with IBD, disease severity and hospitalizations were reduced significantly (<i>p</i> = 0.004 and 0.0234, respectively). In females with IBD, disease severity and hospitalizations were also reduced significantly (<i>p</i> = 0.0001 and 0.0072, respectively). In patients with UC and CD, there were significant improvements in disease severity (<i>p</i> = 0.043 and <i>p</i> = 0.0001, respectively), and CD hospitalizations were also improved (<i>p</i> = 0.0013). In males and females with UC, disease severity was marginally and significantly reduced (<i>p</i> = 0.0781 and <i>p</i> = 0.0379, respectively). In males and females with CD, disease severity was significantly reduced (<i>p</i> = 0.0161 and 0.0003, respectively), and CD male and female hospitalizations were also reduced significantly (<i>p</i> = 0.0436 and 0.013). Analyzing of survey responses, we found that the most patients reported improved IBD symptoms (56%), gained understanding of their condition (84%) and were in favor of continuing STABILITY consultations during infusion therapy (93%). To further investigate the impact of STABILITY, we conducted a comparative analysis between IBD patients undergoing STABILITY infusion therapy and LSUHS patients solely on self-injectable biologics. Our paired data analysis showed significant improvements in disease severity in female IBD patients (1.69 ± 0.13 vs. 1.41 ± 0.12, <i>p</i> = 0.0001) and male IBD patients (1.58 ± 0.16 vs. 1.2 ± 0.135, <i>p</i> = 0.004), in UC patients (1.833 ± 0.4.2 vs. 1.444, <i>p</i> = 0.043), in all CD patients (1.59 ± 0.11 vs. 1.29 ± 0
多项研究表明,患者治疗效果的改善与医患接触的增加有关,尤其是在慢性疾病方面。将这种方法推广到炎症性肠病(IBD)的治疗中是一种很有前景的改善治疗效果的方法。在路易斯安那州立大学什里夫波特分校(LSUHS),一种名为 "STABILITY"(生物治疗过程中的症状回顾)的新方法在 IBD 患者的输液治疗就诊过程中实施。这些简短的 15 分钟医患访谈旨在讨论患者当前的 IBD 相关症状,并评估是否需要更改治疗方案。我们的目标是消除护理空白,防止因错过预约和失去联系而导致症状加重。为了分析 STABILITY 方法的有效性,我们对 2011 年至 2022 年期间在路易斯安那州立大学健康学院就诊的 111 名 IBD 患者(18 名溃疡性结肠炎患者,93 名克罗恩病患者)进行了回顾性病历审查。自2019年3月起,STABILITY成为所有输液治疗就诊的强制要求。收集的数据包括实施 STABILITY 前后患者的人口统计学特征、生物标志物(粪便热保护蛋白、C 反应蛋白和红细胞沉降率)的实验室水平、住院情况、药物更换情况和诊断日期。此外,还采用自愿、匿名的输液患者满意度调查来收集患者对 STABILITY 实施后的反应。在 IBD 男性患者中,疾病严重程度和住院次数明显减少(p = 0.004 和 0.0234)。女性 IBD 患者的疾病严重程度和住院次数也明显减少(p = 0.0001 和 0.0072)。在 UC 和 CD 患者中,疾病严重程度有明显改善(分别为 p = 0.043 和 p = 0.0001),CD 住院治疗情况也有所改善(p = 0.0013)。在男性和女性 UC 患者中,疾病严重程度略有显著降低(分别为 p = 0.0781 和 p = 0.0379)。在男性和女性 CD 患者中,疾病严重程度显著降低(分别为 p = 0.0161 和 0.0003),男性和女性 CD 患者的住院率也显著降低(分别为 p = 0.0436 和 0.013)。通过分析调查反馈,我们发现大多数患者表示 IBD 症状得到了改善(56%),对病情有了更多了解(84%),并赞成在输液治疗期间继续接受 STABILITY 咨询(93%)。为了进一步研究 STABILITY 的影响,我们对接受 STABILITY 输液治疗的 IBD 患者和仅接受自我注射生物制剂治疗的 LSUHS 患者进行了对比分析。我们的配对数据分析显示,女性 IBD 患者(1.69 ± 0.13 vs. 1.41 ± 0.12,p = 0.0001)和男性 IBD 患者(1.58 ± 0.16 vs. 1.2 ± 0.135,p = 0.004)、UC 患者(1.833 ± 0.4.2 vs. 1.444,p = 0.043)、所有 CD 患者(1.59 ± 0.11 vs. 1.29 ± 0.01,p = 0.0001),男性 CD 患者(1.52 ± 0.167 vs. 1.15 ± 0.15,p = 0.016),女性 CD 患者(1.66 ± 0.15 vs. 1.4 ± 0.13,p = 0.0003),女性 UC 患者(1.82 ± 0.32 vs. 1.45 ± 0.31,p = 0.0379),男性 UC 患者略有减少(p = 0.0781)。同样,总体来看,CD 患者的住院率明显降低(0.21 ± 0.04 vs. 0.11 ± 0.03,p = 0.0013),男性 IBD 患者的住院率明显降低(0.175 ± 0.06 vs. 0.05 ± 0.035,p = 0.024), 女性 IBD 患者 (0.21 ± 0.05 vs. 0.11 ± 0.04, p = 0.0072), 男性 CD 患者 (0.18 ± 0.07 vs. 0.06 ± 0.042, p = 0.0436), 以及女性 CD 患者 (0.23 ± 0.06 vs. 0.13 ± 0.04, p = 0.013)。虽然 STABILITY 访谈后粪便钙蛋白、CRP 和血沉的平均值经常降低,但这些数据未达到统计学意义。这些初步研究结果表明,STABILITY 可有效维持 IBD 患者的低疾病活动度或缓解。
{"title":"STABILITY (Symptomatic Review during Biologic Therapy) of Inflammatory Bowel Disease Patients Receiving Infusion Therapy Improves Clinical Outcomes.","authors":"Kelli Morgan, James Morris, Qiang Cai, Phillip Kilgore, Urska Cvek, Marjan Trutschl, Katelynn T Lofton, Meher Sindhoora Mavuram, Prerana Ramesh, Nhi Dao, Ahmed Alhaque, Jonathan Steven Alexander","doi":"10.3390/pathophysiology31030030","DOIUrl":"10.3390/pathophysiology31030030","url":null,"abstract":"<p><p>Several studies have correlate improved patient outcomes with increased physician-patient contacts, particularly in chronic diseases. Extending this approach to inflammatory bowel disease (IBD) care presents a promising means of improving outcomes. At LSU Health Shreveport (LSUHS), a new approach called \"STABILITY\" (Symptomatic Review during Biologic Therapy) was implemented during infusion therapy visits for IBD patients. These brief 15 min physician-patient interviews aimed to discuss the patients' current IBD-related symptoms and evaluate the need for any changes in their treatment plan. Our goal was to remove a care gap and prevent intensifying symptoms created by missed appointments and loss of contact. To analyze the effectiveness of the STABILITY approach, a retrospective chart review was conducted on 111 IBD patients (18 with ulcerative colitis, 93 with Crohn's disease) seen at LSUHS between 2011 and 2022. Since March 2019, STABILITY has been mandatory for all infusion therapy visits. The data collected included patients' demographics, lab levels for biomarkers (fecal calprotectin, C-reactive protein, and erythrocyte sedimentation rates), hospitalizations, medication changes, and diagnosis dates before and after the implementation of STABILITY. Additionally, voluntary, anonymous infusion patient satisfaction surveys post-STABILITY were used to gather patient responses. In males with IBD, disease severity and hospitalizations were reduced significantly (<i>p</i> = 0.004 and 0.0234, respectively). In females with IBD, disease severity and hospitalizations were also reduced significantly (<i>p</i> = 0.0001 and 0.0072, respectively). In patients with UC and CD, there were significant improvements in disease severity (<i>p</i> = 0.043 and <i>p</i> = 0.0001, respectively), and CD hospitalizations were also improved (<i>p</i> = 0.0013). In males and females with UC, disease severity was marginally and significantly reduced (<i>p</i> = 0.0781 and <i>p</i> = 0.0379, respectively). In males and females with CD, disease severity was significantly reduced (<i>p</i> = 0.0161 and 0.0003, respectively), and CD male and female hospitalizations were also reduced significantly (<i>p</i> = 0.0436 and 0.013). Analyzing of survey responses, we found that the most patients reported improved IBD symptoms (56%), gained understanding of their condition (84%) and were in favor of continuing STABILITY consultations during infusion therapy (93%). To further investigate the impact of STABILITY, we conducted a comparative analysis between IBD patients undergoing STABILITY infusion therapy and LSUHS patients solely on self-injectable biologics. Our paired data analysis showed significant improvements in disease severity in female IBD patients (1.69 ± 0.13 vs. 1.41 ± 0.12, <i>p</i> = 0.0001) and male IBD patients (1.58 ± 0.16 vs. 1.2 ± 0.135, <i>p</i> = 0.004), in UC patients (1.833 ± 0.4.2 vs. 1.444, <i>p</i> = 0.043), in all CD patients (1.59 ± 0.11 vs. 1.29 ± 0","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"398-407"},"PeriodicalIF":2.7,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-30DOI: 10.3390/pathophysiology31030029
Collyn O'Quin, Sean D Clayton, Lexus Trosclair, Hannah Meyer, Nhi H Dao, Andrew Minagar, Luke White, Valerie Welch, Giovanni Solitro, Jonathan Steven Alexander, Donald Sorrells
Background: Surgeons often encounter patients with intestinal failure due to inadequate intestinal length ("short bowel syndrome"/SBS). Treatment in these patients remains challenging and the process of physiologic adaptation may take years to complete, which frequently requires parenteral nutrition. We propose a proof-of-concept mechanical bowel elongation approach using a self-expanding prototype of an intestinal expansion sleeve (IES) for use in SBS to accelerate the adaptation process.
Methods: IESs were deployed in the small intestines of Sprague Dawley rats. Mechanical characterization of these prototypes was performed. IES length-tension relationships and post-implant bowel expansion were measured ex vivo. Bowel histology before and after implantation was evaluated.
Results: IES mechanical studies demonstrated decreasing expansive force with elongation. The deployment of IES devices produced an immediate 21 ± 8% increase in bowel length (p < 0.001, n = 11). Mechanical load testing data showed that the IESs expressed maximum expansive forces at 50% compression of the initial pre-contracted length. The small-intestine failure load in the rats was 1.88 ± 21 N. Intestinal histology post deployment of the IES showed significant expansive changes compared to unstretched bowel tissue.
Conclusions: IES devices were scalable to the rat intestinal model in our study. The failure load of the rat small intestine was many times higher than the force exerted by the contraction of the IES. Histology demonstrated preservation of intestinal structure with some mucosal erosion. Future in vivo rat studies on distraction enterogenesis with this IES should help to define this organogenesis phenomenon.
{"title":"Distraction Enterogenesis in Rats: A Novel Approach for the Treatment of Short Bowel Syndrome.","authors":"Collyn O'Quin, Sean D Clayton, Lexus Trosclair, Hannah Meyer, Nhi H Dao, Andrew Minagar, Luke White, Valerie Welch, Giovanni Solitro, Jonathan Steven Alexander, Donald Sorrells","doi":"10.3390/pathophysiology31030029","DOIUrl":"10.3390/pathophysiology31030029","url":null,"abstract":"<p><strong>Background: </strong>Surgeons often encounter patients with intestinal failure due to inadequate intestinal length (\"short bowel syndrome\"/SBS). Treatment in these patients remains challenging and the process of physiologic adaptation may take years to complete, which frequently requires parenteral nutrition. We propose a proof-of-concept mechanical bowel elongation approach using a self-expanding prototype of an intestinal expansion sleeve (IES) for use in SBS to accelerate the adaptation process.</p><p><strong>Methods: </strong>IESs were deployed in the small intestines of Sprague Dawley rats. Mechanical characterization of these prototypes was performed. IES length-tension relationships and post-implant bowel expansion were measured ex vivo. Bowel histology before and after implantation was evaluated.</p><p><strong>Results: </strong>IES mechanical studies demonstrated decreasing expansive force with elongation. The deployment of IES devices produced an immediate 21 ± 8% increase in bowel length (<i>p</i> < 0.001, <i>n</i> = 11). Mechanical load testing data showed that the IESs expressed maximum expansive forces at 50% compression of the initial pre-contracted length. The small-intestine failure load in the rats was 1.88 ± 21 N. Intestinal histology post deployment of the IES showed significant expansive changes compared to unstretched bowel tissue.</p><p><strong>Conclusions: </strong>IES devices were scalable to the rat intestinal model in our study. The failure load of the rat small intestine was many times higher than the force exerted by the contraction of the IES. Histology demonstrated preservation of intestinal structure with some mucosal erosion. Future in vivo rat studies on distraction enterogenesis with this IES should help to define this organogenesis phenomenon.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"388-397"},"PeriodicalIF":2.7,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-28DOI: 10.3390/pathophysiology31030028
Milagros Fuentes-Albero, Mayra Alejandra Mafla-España, José Martínez-Raga, Omar Cauli
Background: Autism spectrum disorder (ASD) is one of the most prevalent neurodevelopmental disorders. Many patients with ASD often show behavioral problems at mealtimes, including food selectivity and atypical feeding behaviors. The Mediterranean diet (MD) has a beneficial effect on mental health for the general population across different ages. There is evidence that good adherence to the MD is effective in reducing peripheral inflammatory markers, such as the cytokine interleukin-6 (IL-6). The present study was designed to evaluate adherence to the MD in children with ASD using age- and sex-matched, typically developing individuals (TDs) as a control group and to determine whether differences in adherence to the MD are associated with salivary IL-6 and IL-6 receptor concentration.
Methods: Twenty children and adolescents with ASD (mean age 9.95 ± 0.65 years) and twenty TDs (mean age: 9.85 ± 0.59 years) participated in this study (N = 16 males and N = 4 females in each group). Participants with ASD were enrolled in a psychiatric consultation in Valencia (Spain), and TDs were recruited from two public schools in Valencia. The parents of both ASD and TD groups answered the items in a validated Mediterranean Diet Quality Index for children and adolescents (KIDMED) questionnaire on their children's adherence to the MD.
Results: The mean adherence to MD score was significantly lower in the ASD group (9.10 ± 0.42) (range 6-12) than in the TD group (10.35 ± 0.31) (range 8-12) (p = 0.02, Mann-Whitney U test). There was no statistically significant association between adherence to the MD and age or sex in both groups, but there was a significant correlation between the total KIDMED score and body mass index (BMI) in the ASD group. Regarding the concentration of Il-6 and the Il-6 receptor in saliva samples, there were no significant differences between the two groups; however, linear regression analysis by group revealed significant associations between the adherence to MD score and the concentration of IL-6 and its receptor in saliva in the ASD group (p = 0.003, OR = 0.68, 95% CI 0.007 to -0.02; p = 0.009, OR = -0.64, 95% CI -0.01 to -0.00). In contrast, no significant associations were observed between the adherence to MD score and the concentration of IL-6 and its receptor in saliva in the TD group.
Conclusions: Children and adolescents with ASD showed significantly lower adherence to the MD, which can contribute to nutritional deficits described in ASD, and the role of BMI composition (fat versus lean mass) needs to be further investigated in this group. The concentration of IL-6 and its receptor in saliva is associated with adherence to the MD, suggesting a possible link between IL-6 and diet in ASD. Further studies to clarify the associations between IL-6, psychiatric alterations, and diet in ASD are needed.
{"title":"Autistic Children/Adolescents Have Lower Adherence to the Mediterranean Diet and Higher Salivary IL-6 Concentration: Potential Diet-Inflammation Links?","authors":"Milagros Fuentes-Albero, Mayra Alejandra Mafla-España, José Martínez-Raga, Omar Cauli","doi":"10.3390/pathophysiology31030028","DOIUrl":"10.3390/pathophysiology31030028","url":null,"abstract":"<p><strong>Background: </strong>Autism spectrum disorder (ASD) is one of the most prevalent neurodevelopmental disorders. Many patients with ASD often show behavioral problems at mealtimes, including food selectivity and atypical feeding behaviors. The Mediterranean diet (MD) has a beneficial effect on mental health for the general population across different ages. There is evidence that good adherence to the MD is effective in reducing peripheral inflammatory markers, such as the cytokine interleukin-6 (IL-6). The present study was designed to evaluate adherence to the MD in children with ASD using age- and sex-matched, typically developing individuals (TDs) as a control group and to determine whether differences in adherence to the MD are associated with salivary IL-6 and IL-6 receptor concentration.</p><p><strong>Methods: </strong>Twenty children and adolescents with ASD (mean age 9.95 ± 0.65 years) and twenty TDs (mean age: 9.85 ± 0.59 years) participated in this study (N = 16 males and N = 4 females in each group). Participants with ASD were enrolled in a psychiatric consultation in Valencia (Spain), and TDs were recruited from two public schools in Valencia. The parents of both ASD and TD groups answered the items in a validated Mediterranean Diet Quality Index for children and adolescents (KIDMED) questionnaire on their children's adherence to the MD.</p><p><strong>Results: </strong>The mean adherence to MD score was significantly lower in the ASD group (9.10 ± 0.42) (range 6-12) than in the TD group (10.35 ± 0.31) (range 8-12) (<i>p</i> = 0.02, Mann-Whitney U test). There was no statistically significant association between adherence to the MD and age or sex in both groups, but there was a significant correlation between the total KIDMED score and body mass index (BMI) in the ASD group. Regarding the concentration of Il-6 and the Il-6 receptor in saliva samples, there were no significant differences between the two groups; however, linear regression analysis by group revealed significant associations between the adherence to MD score and the concentration of IL-6 and its receptor in saliva in the ASD group (<i>p</i> = 0.003, OR = 0.68, 95% CI 0.007 to -0.02; <i>p</i> = 0.009, OR = -0.64, 95% CI -0.01 to -0.00). In contrast, no significant associations were observed between the adherence to MD score and the concentration of IL-6 and its receptor in saliva in the TD group.</p><p><strong>Conclusions: </strong>Children and adolescents with ASD showed significantly lower adherence to the MD, which can contribute to nutritional deficits described in ASD, and the role of BMI composition (fat versus lean mass) needs to be further investigated in this group. The concentration of IL-6 and its receptor in saliva is associated with adherence to the MD, suggesting a possible link between IL-6 and diet in ASD. Further studies to clarify the associations between IL-6, psychiatric alterations, and diet in ASD are needed.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"376-387"},"PeriodicalIF":2.7,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-30DOI: 10.3390/pathophysiology31030024
Jay Patel, Sonu M M Bhaskar
Background: Atrial fibrillation (AF) significantly contributes to acute ischemic stroke, with undetected AF being a common culprit in cryptogenic strokes. N-terminal pro-B-type natriuretic peptide (NT-proBNP), indicative of myocardial stress, has been proposed as a biomarker for AF detection, aiding in the selection of patients for extended cardiac monitoring. However, the diagnostic accuracy of NT-proBNP remains uncertain.
Methods: We conducted a meta-analysis to evaluate the diagnostic accuracy of NT-proBNP in detecting AF among cryptogenic stroke patients. A comprehensive literature search was conducted across PubMed, Embase, and Cochrane databases to identify relevant studies. Studies reporting NT-proBNP levels in stroke patients and data on the proportion of patients with AF above a specified cut-off were included. Meta-analyses were performed using the midas command in STATA.
Results: Seven studies encompassing 2171 patients were included in the analysis, of which five studies contained cohorts with cryptogenic strokes. Among patients with cryptogenic stroke, NT-proBNP demonstrated a diagnostic accuracy of 80% (Area Under the Receiver Operating Curve 0.80 [95% CI 0.76-0.83]), with a sensitivity of 81% (95% CI 0.68-0.89) and a specificity of 68% (95% CI 0.60-0.75).
Conclusion: Our meta-analysis indicates that NT-proBNP exhibits a good-to-very-good diagnostic accuracy for detecting AF in patients with cryptogenic stroke. These findings suggest potential implications for utilizing NT-proBNP in guiding the selection of patients for prolonged cardiac monitoring, thereby aiding in the management of cryptogenic stroke cases.
背景:心房颤动(房颤)是急性缺血性脑卒中的重要诱因,而未被发现的房颤则是隐源性脑卒中的常见罪魁祸首。提示心肌应激的 N 端前 B 型钠尿肽(NT-proBNP)被认为是检测房颤的生物标志物,有助于选择患者进行长期心脏监测。然而,NT-proBNP 的诊断准确性仍不确定:我们进行了一项荟萃分析,以评估 NT-proBNP 在隐源性卒中患者中检测房颤的诊断准确性。我们在 PubMed、Embase 和 Cochrane 数据库中进行了全面的文献检索,以确定相关研究。纳入了报告卒中患者 NT-proBNP 水平的研究以及房颤患者比例超过特定临界值的数据。使用 STATA 中的 midas 命令进行 Meta 分析:共有 7 项研究纳入分析,涵盖 2171 名患者,其中 5 项研究包含隐源性脑卒中队列。在隐源性卒中患者中,NT-proBNP 的诊断准确率为 80%(接收者工作曲线下面积为 0.80 [95% CI 0.76-0.83]),敏感性为 81%(95% CI 0.68-0.89),特异性为 68%(95% CI 0.60-0.75):我们的荟萃分析表明,NT-proBNP 对隐源性卒中患者房颤的检测具有良好至非常好的诊断准确性。这些研究结果表明,利用 NT-proBNP 指导选择患者进行长期心脏监测具有潜在的意义,从而有助于隐源性卒中病例的管理。
{"title":"Diagnostic Utility of N-Terminal Pro-B-Type Natriuretic Peptide in Identifying Atrial Fibrillation Post-Cryptogenic Stroke: A Systematic Review and Meta-Analysis.","authors":"Jay Patel, Sonu M M Bhaskar","doi":"10.3390/pathophysiology31030024","DOIUrl":"10.3390/pathophysiology31030024","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) significantly contributes to acute ischemic stroke, with undetected AF being a common culprit in cryptogenic strokes. N-terminal pro-B-type natriuretic peptide (NT-proBNP), indicative of myocardial stress, has been proposed as a biomarker for AF detection, aiding in the selection of patients for extended cardiac monitoring. However, the diagnostic accuracy of NT-proBNP remains uncertain.</p><p><strong>Methods: </strong>We conducted a meta-analysis to evaluate the diagnostic accuracy of NT-proBNP in detecting AF among cryptogenic stroke patients. A comprehensive literature search was conducted across PubMed, Embase, and Cochrane databases to identify relevant studies. Studies reporting NT-proBNP levels in stroke patients and data on the proportion of patients with AF above a specified cut-off were included. Meta-analyses were performed using the midas command in STATA.</p><p><strong>Results: </strong>Seven studies encompassing 2171 patients were included in the analysis, of which five studies contained cohorts with cryptogenic strokes. Among patients with cryptogenic stroke, NT-proBNP demonstrated a diagnostic accuracy of 80% (Area Under the Receiver Operating Curve 0.80 [95% CI 0.76-0.83]), with a sensitivity of 81% (95% CI 0.68-0.89) and a specificity of 68% (95% CI 0.60-0.75).</p><p><strong>Conclusion: </strong>Our meta-analysis indicates that NT-proBNP exhibits a good-to-very-good diagnostic accuracy for detecting AF in patients with cryptogenic stroke. These findings suggest potential implications for utilizing NT-proBNP in guiding the selection of patients for prolonged cardiac monitoring, thereby aiding in the management of cryptogenic stroke cases.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"331-349"},"PeriodicalIF":2.7,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Understanding how gut flora interacts with oxidative stress has been the subject of significant research in recent years. There is much evidence demonstrating the existence of the microbiome-oxidative stress interaction. However, the biochemical basis of this interaction is still unclear. In this narrative review, possible pathways of the gut microbiota and oxidative stress interaction are presented, among which genetic underpinnings play an important role. Trimethylamine-N-oxide, mitochondria, short-chain fatty acids, and melatonin also appear to play roles. Moreover, the relationship between oxidative stress and the gut microbiome in obesity, metabolic syndrome, chronic ethanol consumption, dietary supplements, and medications is considered. An investigation of the correlation between bacterial community features and OS parameter changes under normal and pathological conditions might provide information for the determination of new research methods. Furthermore, such research could contribute to establishing a foundation for determining the linkers in the microbiome-OS association.
{"title":"Gut Microbiome Interactions with Oxidative Stress: Mechanisms and Consequences for Health.","authors":"Natalya Semenova, Nadezhda Garashchenko, Sergey Kolesnikov, Marina Darenskaya, Liubov Kolesnikova","doi":"10.3390/pathophysiology31030023","DOIUrl":"10.3390/pathophysiology31030023","url":null,"abstract":"<p><p>Understanding how gut flora interacts with oxidative stress has been the subject of significant research in recent years. There is much evidence demonstrating the existence of the microbiome-oxidative stress interaction. However, the biochemical basis of this interaction is still unclear. In this narrative review, possible pathways of the gut microbiota and oxidative stress interaction are presented, among which genetic underpinnings play an important role. Trimethylamine-N-oxide, mitochondria, short-chain fatty acids, and melatonin also appear to play roles. Moreover, the relationship between oxidative stress and the gut microbiome in obesity, metabolic syndrome, chronic ethanol consumption, dietary supplements, and medications is considered. An investigation of the correlation between bacterial community features and OS parameter changes under normal and pathological conditions might provide information for the determination of new research methods. Furthermore, such research could contribute to establishing a foundation for determining the linkers in the microbiome-OS association.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 3","pages":"309-330"},"PeriodicalIF":2.7,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-27DOI: 10.3390/pathophysiology31020020
Anna Starshinova, Anastasia Borozinets, Anastasia Kulpina, Vitaliy Sereda, Artem Rubinstein, Igor Kudryavtsev, Dmitry Kudlay
Bronchial asthma (BA) continues to be a difficult disease to diagnose. Various factors have been described in the development of BA, but to date, there is no clear evidence for the etiology of this chronic disease. The emergence of COVID-19 has contributed to the pandemic course of asthma and immunologic features. However, there are no unambiguous data on asthma on the background and after COVID-19. There is correlation between various trigger factors that provoke the development of bronchial asthma. It is now obvious that the SARS-CoV-2 virus is one of the provoking factors. COVID-19 has affected the course of asthma. Currently, there is no clear understanding of whether asthma progresses during or after COVID-19 infection. According to the results of some studies, a significant difference was identified between the development of asthma in people after COVID-19. Mild asthma and moderate asthma do not increase the severity of COVID-19 infection. Nevertheless, oral steroid treatment and hospitalization for severe BA were associated with higher COVID-19 severity. The influence of SARS-CoV-2 infection is one of the protective factors. It causes the development of severe bronchial asthma. The accumulated experience with omalizumab in patients with severe asthma during COVID-19, who received omalizumab during the pandemic, has strongly suggested that continued treatment with omalizumab is safe and may help prevent the severe course of COVID-19. Targeted therapy for asthma with the use of omalizumab may also help to reduce severe asthma associated with COVID-19. However, further studies are needed to prove the effect of omalizumab. Data analysis should persist, based on the results of the course of asthma after COVID-19 with varying degrees of severity.
{"title":"Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.","authors":"Anna Starshinova, Anastasia Borozinets, Anastasia Kulpina, Vitaliy Sereda, Artem Rubinstein, Igor Kudryavtsev, Dmitry Kudlay","doi":"10.3390/pathophysiology31020020","DOIUrl":"10.3390/pathophysiology31020020","url":null,"abstract":"<p><p>Bronchial asthma (BA) continues to be a difficult disease to diagnose. Various factors have been described in the development of BA, but to date, there is no clear evidence for the etiology of this chronic disease. The emergence of COVID-19 has contributed to the pandemic course of asthma and immunologic features. However, there are no unambiguous data on asthma on the background and after COVID-19. There is correlation between various trigger factors that provoke the development of bronchial asthma. It is now obvious that the SARS-CoV-2 virus is one of the provoking factors. COVID-19 has affected the course of asthma. Currently, there is no clear understanding of whether asthma progresses during or after COVID-19 infection. According to the results of some studies, a significant difference was identified between the development of asthma in people after COVID-19. Mild asthma and moderate asthma do not increase the severity of COVID-19 infection. Nevertheless, oral steroid treatment and hospitalization for severe BA were associated with higher COVID-19 severity. The influence of SARS-CoV-2 infection is one of the protective factors. It causes the development of severe bronchial asthma. The accumulated experience with omalizumab in patients with severe asthma during COVID-19, who received omalizumab during the pandemic, has strongly suggested that continued treatment with omalizumab is safe and may help prevent the severe course of COVID-19. Targeted therapy for asthma with the use of omalizumab may also help to reduce severe asthma associated with COVID-19. However, further studies are needed to prove the effect of omalizumab. Data analysis should persist, based on the results of the course of asthma after COVID-19 with varying degrees of severity.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 2","pages":"269-287"},"PeriodicalIF":2.7,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11206645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-29DOI: 10.3390/pathophysiology31020014
Marina Vulić, Branislav Milovanovic, Ante Obad, Duška Glavaš, Igor Glavicic, Damir Zubac, Maja Valic, Zoran Valic
The present study investigated the influence of SCUBA dives with compressed air at depths of 10 and 20 m on ECG-derived HRV parameters in apparently healthy individuals. We hypothesized that cardiac sympathetic activity (measured by HRV parameters) adapts proportionally to diving depth, and that both time- and frequency-domain parameters are sensitive enough to track changes in cardiac ANS function during diving activities and subsequently during the recovery period. Eleven healthy middle-aged recreational divers (nine men and two women, age 43 ± 8, all nonsmokers) volunteered to participate in the present study. The participants (all open-circuit divers) were equipped with dry suits and ECG Holter devices and were later randomly assigned to dive pairs and depths (10 m vs. 20 m), and each participant served as his or her own control. No interaction effects (diving depth x time epoch) were found for the most commonly used HRV markers. More precisely, in response to two different diving protocols, a significant post hoc effect of time was observed for HR and SDNN, as these parameters transiently decreased during the dives and returned to baseline after ascent (p < 0.001). The ULF, VLF (p < 0.003), TP, and LF parameters decreased significantly during the dives, while HF significantly increased (p < 0.003). SCUBA diving apparently challenges the cardiac ANS, even in healthy individuals. The observed changes reveal possible underwater methods of influencing the parasympathetic activity of the heart depending on the depth of the dive. These results identify autonomic nervous system markers to track the cardiovascular risk related to diving and point to the possibility of tracking cardiovascular system benefits during underwater activities in selected patients.
{"title":"Depth of SCUBA Diving Affects Cardiac Autonomic Nervous System.","authors":"Marina Vulić, Branislav Milovanovic, Ante Obad, Duška Glavaš, Igor Glavicic, Damir Zubac, Maja Valic, Zoran Valic","doi":"10.3390/pathophysiology31020014","DOIUrl":"https://doi.org/10.3390/pathophysiology31020014","url":null,"abstract":"<p><p>The present study investigated the influence of SCUBA dives with compressed air at depths of 10 and 20 m on ECG-derived HRV parameters in apparently healthy individuals. We hypothesized that cardiac sympathetic activity (measured by HRV parameters) adapts proportionally to diving depth, and that both time- and frequency-domain parameters are sensitive enough to track changes in cardiac ANS function during diving activities and subsequently during the recovery period. Eleven healthy middle-aged recreational divers (nine men and two women, age 43 ± 8, all nonsmokers) volunteered to participate in the present study. The participants (all open-circuit divers) were equipped with dry suits and ECG Holter devices and were later randomly assigned to dive pairs and depths (10 m vs. 20 m), and each participant served as his or her own control. No interaction effects (diving depth x time epoch) were found for the most commonly used HRV markers. More precisely, in response to two different diving protocols, a significant post hoc effect of time was observed for HR and SDNN, as these parameters transiently decreased during the dives and returned to baseline after ascent (<i>p</i> < 0.001). The ULF, VLF (<i>p</i> < 0.003), TP, and LF parameters decreased significantly during the dives, while HF significantly increased (<i>p</i> < 0.003). SCUBA diving apparently challenges the cardiac ANS, even in healthy individuals. The observed changes reveal possible underwater methods of influencing the parasympathetic activity of the heart depending on the depth of the dive. These results identify autonomic nervous system markers to track the cardiovascular risk related to diving and point to the possibility of tracking cardiovascular system benefits during underwater activities in selected patients.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 2","pages":"183-189"},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11036274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-28DOI: 10.3390/pathophysiology31010009
Olanrewaju Oladosu, Emma Chin, Christian Barksdale, Rhonda R Powell, Terri Bruce, Alexis Stamatikos
Atherosclerosis is caused by cholesterol accumulation within arteries. The intima is where atherosclerotic plaque accumulates and where lipid-laden foam cells reside. Intimal foam cells comprise of both monocyte-derived macrophages and macrophage-like cells (MLC) of vascular smooth muscle cell (VSMC) origin. Foam cells can remove cholesterol via apoAI-mediated cholesterol efflux and this process is regulated by the transporter ABCA1. The microRNA miR-33a-5p is thought to be atherogenic via silencing ABCA1 which promotes cholesterol retention and data has shown inhibiting miR-33a-5p in macrophages may be atheroprotective via enhancing apoAI-mediated cholesterol efflux. However, it is not entirely elucidated whether precisely inhibiting miR-33a-5p in MLC also increases ABCA1-dependent cholesterol efflux. Therefore, the purpose of this work is to test the hypothesis that inhibition of miR-33a-5p in cultured MLC enhances apoAI-mediated cholesterol efflux. In our study, we utilized the VSMC line MOVAS cells in our experiments, and cholesterol-loaded MOVAS cells to convert this cell line into MLC. Inhibition of miR-33a-5p was accomplished by transducing cells with a lentivirus that expresses an antagomiR directed at miR-33a-5p. Expression of miR-33a-5p was analyzed by qRT-PCR, ABCA1 protein expression was assessed via immunoblotting, and apoAI-mediated cholesterol efflux was measured using cholesterol efflux assays. In our results, we demonstrated that lentiviral vector-mediated knockdown of miR-33a-5p resulted in decreasing expression of this microRNA in cultured MLC. Moreover, reduction of miR-33a-5p in cultured MLC resulted in de-repression of ABCA1 expression, which caused ABCA1 protein upregulation in cultured MLC. Additionally, this increase in ABCA1 protein expression resulted in enhancing ABCA1-dependent cholesterol efflux through increasing apoAI-mediated cholesterol efflux in cultured MLC. From these findings, we conclude that inhibiting miR-33a-5p in MLC may protect against atherosclerosis by promoting ABCA1-dependent cholesterol efflux.
{"title":"Inhibition of miR-33a-5p in Macrophage-like Cells In Vitro Promotes apoAI-Mediated Cholesterol Efflux.","authors":"Olanrewaju Oladosu, Emma Chin, Christian Barksdale, Rhonda R Powell, Terri Bruce, Alexis Stamatikos","doi":"10.3390/pathophysiology31010009","DOIUrl":"10.3390/pathophysiology31010009","url":null,"abstract":"<p><p>Atherosclerosis is caused by cholesterol accumulation within arteries. The intima is where atherosclerotic plaque accumulates and where lipid-laden foam cells reside. Intimal foam cells comprise of both monocyte-derived macrophages and macrophage-like cells (MLC) of vascular smooth muscle cell (VSMC) origin. Foam cells can remove cholesterol via apoAI-mediated cholesterol efflux and this process is regulated by the transporter ABCA1. The microRNA miR-33a-5p is thought to be atherogenic via silencing ABCA1 which promotes cholesterol retention and data has shown inhibiting miR-33a-5p in macrophages may be atheroprotective via enhancing apoAI-mediated cholesterol efflux. However, it is not entirely elucidated whether precisely inhibiting miR-33a-5p in MLC also increases ABCA1-dependent cholesterol efflux. Therefore, the purpose of this work is to test the hypothesis that inhibition of miR-33a-5p in cultured MLC enhances apoAI-mediated cholesterol efflux. In our study, we utilized the VSMC line MOVAS cells in our experiments, and cholesterol-loaded MOVAS cells to convert this cell line into MLC. Inhibition of miR-33a-5p was accomplished by transducing cells with a lentivirus that expresses an antagomiR directed at miR-33a-5p. Expression of miR-33a-5p was analyzed by qRT-PCR, ABCA1 protein expression was assessed via immunoblotting, and apoAI-mediated cholesterol efflux was measured using cholesterol efflux assays. In our results, we demonstrated that lentiviral vector-mediated knockdown of miR-33a-5p resulted in decreasing expression of this microRNA in cultured MLC. Moreover, reduction of miR-33a-5p in cultured MLC resulted in de-repression of ABCA1 expression, which caused ABCA1 protein upregulation in cultured MLC. Additionally, this increase in ABCA1 protein expression resulted in enhancing ABCA1-dependent cholesterol efflux through increasing apoAI-mediated cholesterol efflux in cultured MLC. From these findings, we conclude that inhibiting miR-33a-5p in MLC may protect against atherosclerosis by promoting ABCA1-dependent cholesterol efflux.</p>","PeriodicalId":19852,"journal":{"name":"Pathophysiology","volume":"31 1","pages":"117-126"},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10976131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140294231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}